CL2013000850A1 - Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros. - Google Patents

Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.

Info

Publication number: CL2013000850A1
Authority: CL; Chile
Prior art keywords: carcionoma; mammary; trifluoro; morpholinyl; pyrimidinyl
Prior art date: 2010-10-01

Application number

CL2013000850A

Other languages

English (en)

Inventor

John Vincent Calienni

La Cruz Marilyn De

Dietmar Flubacher

Baoqing Gong

Prasad Koteswara Kapa

Piotr H Karpinski

Hui Lui

Pascal Michael

Rasmus Mose

Maria Caterina Testa

Liladhar Murlidhar Waykole

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-01

Filing date

2013-03-28

Publication date

2013-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44773179&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-28 Application filed by Novartis Ag filed Critical Novartis Ag

2013-09-27 Publication of CL2013000850A1 publication Critical patent/CL2013000850A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

CL2013000850A 2010-10-01 2013-03-28 Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros. CL2013000850A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38872110P	2010-10-01	2010-10-01
US201161494915P	2011-06-09	2011-06-09

Publications (1)

Publication Number	Publication Date
CL2013000850A1 true CL2013000850A1 (es)	2013-09-27

Family

ID=44773179

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2013000850A CL2013000850A1 (es)	2010-10-01	2013-03-28	Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.
CL2015001088A CL2015001088A1 (es)	2010-10-01	2015-04-27	Proceso de elaboración de compuestos derivados de pirimidina (div. sol. 850-13).

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL2015001088A CL2015001088A1 (es)	2010-10-01	2015-04-27	Proceso de elaboración de compuestos derivados de pirimidina (div. sol. 850-13).

Country Status (31)

Country	Link
US (3)	US9181215B2 (es)
EP (2)	EP3040333B1 (es)
JP (3)	JP5998145B2 (es)
KR (2)	KR20130119928A (es)
CN (3)	CN103140479B (es)
AR (1)	AR083213A1 (es)
AU (4)	AU2011308856B2 (es)
BR (1)	BR112013007123B1 (es)
CA (1)	CA2813333C (es)
CL (2)	CL2013000850A1 (es)
CO (1)	CO6700837A2 (es)
DK (1)	DK3040333T3 (es)
EC (1)	ECSP13012596A (es)
ES (1)	ES2699951T3 (es)
GT (1)	GT201300080A (es)
HK (1)	HK1220686A1 (es)
HU (1)	HUE041326T2 (es)
IL (3)	IL225113A (es)
LT (1)	LT3040333T (es)
MX (1)	MX354482B (es)
MY (1)	MY160785A (es)
NZ (1)	NZ608285A (es)
PE (1)	PE20140002A1 (es)
PH (1)	PH12015501585A1 (es)
PL (1)	PL3040333T3 (es)
PT (1)	PT3040333T (es)
RU (2)	RU2576619C2 (es)
SG (1)	SG188439A1 (es)
SI (1)	SI3040333T1 (es)
TW (1)	TWI540133B (es)
WO (1)	WO2012044727A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA114178C2 (uk)	2011-07-01	2017-05-10	Новартіс Аг	Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
AU2012313888B2 (en)	2011-09-27	2016-03-31	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
UY34632A (es)	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
ES2605638T3 (es) *	2012-10-23	2017-03-15	Novartis Ag	Proceso Mejorado para fabricar 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AP2015008707A0 (en)	2013-03-14	2015-09-30	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9318944B2 (en)	2013-04-29	2016-04-19	Rockwell Automation Technologies, Inc.	Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en)	2013-10-01	2016-03-22	Rockwell Automation Technologies, Inc.	Method and apparatus for detecting AFE filter capacitor degradation
WO2015055071A1 (zh) *	2013-10-16	2015-04-23	上海璎黎药业有限公司	稠合杂环化合物、其制备方法、药物组合物和用途
JP6513105B2 (ja) *	2014-04-22	2019-05-15	ウニヴェルズィテートバーゼル	トリアジン、ピリミジン及びピリジン誘導体の新規製造方法
CN105085476B (zh) *	2014-11-24	2018-03-09	苏州晶云药物科技有限公司	5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
EP3235816B1 (en) *	2014-12-17	2020-02-12	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
US9481665B2 (en) *	2015-03-13	2016-11-01	Yong Xu	Process for preparing PI3K inhibitor buparsilib
WO2016151501A1 (en)	2015-03-25	2016-09-29	Novartis Ag	Pharmaceutical combinations
CN105001151B (zh) *	2015-08-28	2017-07-14	苏州明锐医药科技有限公司	布帕尼西中间体及其制备方法
CN106543140A (zh) *	2015-09-21	2017-03-29	苏州晶云药物科技有限公司	5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
ES2907574T3 (es) *	2015-12-16	2022-04-25	Genentech Inc	Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer.
CN106905294A (zh) *	2016-07-08	2017-06-30	苏州科睿思制药有限公司	5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) *	2017-08-03	2018-03-13	上海厚璞生物科技有限公司	一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) *	2019-04-30	2021-08-03	合肥工业大学	一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6124476A (en)	1998-04-17	2000-09-26	Symyx Technologies, Inc.	Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) *	2002-11-11	2006-02-15	拜耳医药保健股份公司	作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
EP2316831B1 (en)	2002-11-21	2013-03-06	Novartis AG	2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
KR101435231B1 (ko)	2006-08-24	2014-10-02	아스트라제네카 아베	증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
WO2008098058A1 (en)	2007-02-06	2008-08-14	Novartis Ag	Pi 3-kinase inhibitors and methods of their use
WO2009066084A1 (en) *	2007-11-21	2009-05-28	F. Hoffmann-La Roche Ag	2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
US20120059005A1 (en)	2009-05-15	2012-03-08	Novartis Ag	Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases

2011
- 2011-09-29 BR BR112013007123-0A patent/BR112013007123B1/pt active IP Right Grant
- 2011-09-29 EP EP16151719.8A patent/EP3040333B1/en active Active
- 2011-09-29 PL PL16151719T patent/PL3040333T3/pl unknown
- 2011-09-29 HU HUE16151719A patent/HUE041326T2/hu unknown
- 2011-09-29 JP JP2013531796A patent/JP5998145B2/ja active Active
- 2011-09-29 KR KR1020137011172A patent/KR20130119928A/ko active Application Filing
- 2011-09-29 CA CA2813333A patent/CA2813333C/en active Active
- 2011-09-29 CN CN201180047753.2A patent/CN103140479B/zh active Active
- 2011-09-29 SI SI201131619T patent/SI3040333T1/sl unknown
- 2011-09-29 ES ES16151719T patent/ES2699951T3/es active Active
- 2011-09-29 MY MYPI2013000811A patent/MY160785A/en unknown
- 2011-09-29 PE PE2013000654A patent/PE20140002A1/es active IP Right Grant
- 2011-09-29 AR ARP110103595A patent/AR083213A1/es unknown
- 2011-09-29 EP EP11767362.4A patent/EP2621908A2/en not_active Withdrawn
- 2011-09-29 AU AU2011308856A patent/AU2011308856B2/en active Active
- 2011-09-29 CN CN201510156027.4A patent/CN104987321A/zh active Pending
- 2011-09-29 RU RU2013120326/04A patent/RU2576619C2/ru active
- 2011-09-29 WO PCT/US2011/053808 patent/WO2012044727A2/en active Application Filing
- 2011-09-29 DK DK16151719.8T patent/DK3040333T3/da active
- 2011-09-29 PT PT16151719T patent/PT3040333T/pt unknown
- 2011-09-29 CN CN201510157366.4A patent/CN104945373A/zh active Pending
- 2011-09-29 RU RU2015150728A patent/RU2015150728A/ru unknown
- 2011-09-29 LT LTEP16151719.8T patent/LT3040333T/lt unknown
- 2011-09-29 MX MX2013003507A patent/MX354482B/es active IP Right Grant
- 2011-09-29 NZ NZ608285A patent/NZ608285A/en not_active IP Right Cessation
- 2011-09-29 SG SG2013016837A patent/SG188439A1/en unknown
- 2011-09-29 US US13/825,880 patent/US9181215B2/en active Active
- 2011-09-29 KR KR1020187032263A patent/KR20180123586A/ko not_active Application Discontinuation
- 2011-09-30 TW TW100135673A patent/TWI540133B/zh active
2013
- 2013-03-07 IL IL225113A patent/IL225113A/en unknown
- 2013-03-22 GT GT201300080A patent/GT201300080A/es unknown
- 2013-03-22 CO CO13057091A patent/CO6700837A2/es unknown
- 2013-03-28 CL CL2013000850A patent/CL2013000850A1/es unknown
- 2013-04-30 EC ECSP13012596 patent/ECSP13012596A/es unknown
- 2013-09-24 HK HK16108618.7A patent/HK1220686A1/zh unknown
2014
- 2014-06-19 IL IL233282A patent/IL233282A/en unknown
2015
- 2015-02-24 AU AU2015200936A patent/AU2015200936A1/en not_active Abandoned
- 2015-02-24 AU AU2015200938A patent/AU2015200938B2/en not_active Ceased
- 2015-03-30 IL IL238046A patent/IL238046A/en not_active IP Right Cessation
- 2015-04-27 CL CL2015001088A patent/CL2015001088A1/es unknown
- 2015-05-06 US US14/705,013 patent/US9359326B2/en not_active Expired - Fee Related
- 2015-07-20 PH PH12015501585A patent/PH12015501585A1/en unknown
- 2015-10-23 AU AU2015246141A patent/AU2015246141B2/en not_active Ceased
- 2015-12-17 JP JP2015246501A patent/JP2016128414A/ja active Pending
- 2015-12-17 JP JP2015246502A patent/JP2016106091A/ja active Pending
2016
- 2016-05-06 US US15/147,986 patent/US9452994B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20130225571A1 (en)	2013-08-29
CA2813333C (en)	2019-01-15
RU2015150728A (ru)	2019-01-15
SI3040333T1 (sl)	2019-01-31
RU2576619C2 (ru)	2016-03-10
PT3040333T (pt)	2018-12-04
JP2016128414A (ja)	2016-07-14
IL238046A (en)	2016-08-31
MX2013003507A (es)	2013-05-20
CN104945373A (zh)	2015-09-30
ECSP13012596A (es)	2013-07-31
CA2813333A1 (en)	2012-04-05
WO2012044727A3 (en)	2012-06-07
JP2016106091A (ja)	2016-06-16
DK3040333T3 (da)	2019-01-02
BR112013007123B1 (pt)	2021-11-09
EP2621908A2 (en)	2013-08-07
ES2699951T3 (es)	2019-02-13
US9452994B2 (en)	2016-09-27
JP2013541536A (ja)	2013-11-14
IL233282A (en)	2016-08-31
AU2015246141B2 (en)	2016-07-07
CN104987321A (zh)	2015-10-21
LT3040333T (lt)	2018-12-10
PE20140002A1 (es)	2014-01-21
MY160785A (en)	2017-03-15
AU2015200938B2 (en)	2015-11-19
AU2015200936A1 (en)	2015-03-12
AR083213A1 (es)	2013-02-06
KR20180123586A (ko)	2018-11-16
US9181215B2 (en)	2015-11-10
TWI540133B (zh)	2016-07-01
NZ608285A (en)	2014-06-27
SG188439A1 (en)	2013-05-31
JP5998145B2 (ja)	2016-09-28
US9359326B2 (en)	2016-06-07
CN103140479A (zh)	2013-06-05
CN103140479B (zh)	2015-04-08
CO6700837A2 (es)	2013-06-28
PL3040333T3 (pl)	2019-03-29
TW201215605A (en)	2012-04-16
AU2015246141A1 (en)	2015-11-12
WO2012044727A2 (en)	2012-04-05
US20150232446A1 (en)	2015-08-20
PH12015501585A1 (en)	2015-09-21
HK1220686A1 (zh)	2017-05-12
IL233282A0 (en)	2014-08-31
EP3040333B1 (en)	2018-09-12
RU2013120326A (ru)	2014-11-20
IL225113A (en)	2016-08-31
GT201300080A (es)	2014-07-18
AU2011308856A1 (en)	2013-03-28
MX354482B (es)	2018-03-07
EP3040333A1 (en)	2016-07-06
HUE041326T2 (hu)	2019-05-28
AU2011308856B2 (en)	2015-04-23
BR112013007123A2 (pt)	2016-06-14
US20160251334A1 (en)	2016-09-01
AU2015200938A1 (en)	2015-03-12
KR20130119928A (ko)	2013-11-01
CL2015001088A1 (es)	2015-07-10

Publication	Publication Date	Title
CL2013000850A1 (es)	2013-09-27	Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.
BRPI1013426A2 (pt)	2016-11-08	organismos para produção de 1,3-butanodiol
CU20170087A7 (es)	2017-11-07	Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
CL2009000990A1 (es)	2010-10-15	Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
FR2962442B1 (fr)	2016-02-26	Composition stable de 2,3,3,3-tetrafluoropropene
FR2911878B1 (fr)	2012-11-02	Procede de preparation de polyhydroxy-urethanes.
PE20140983A1 (es)	2014-08-25	Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
CL2014002334A1 (es)	2015-04-17	Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
BRPI0822722A2 (pt)	2015-07-07	Implemento para cuidado oral.
CL2014000175A1 (es)	2014-08-22	Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.
IL232235A0 (en)	2014-06-30	1, 2, 5-converted oxadiazole compounds and their use as herbicides
BRPI0906802A2 (pt)	2015-07-14	Implemento para cuidado oral.
DK3309139T3 (da)	2023-12-18	Process for the preparation of 2,3,3,3-trifluoropropene
UY32598A (es)	2010-12-31	Sal de abt-263 y formas en estado sólido de la misma
CO6880069A2 (es)	2014-02-28	Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
ECSP10010704A (es)	2011-01-31	Sales y polimorfos de un compuesto de tetraticlina
BR112013003529A2 (pt)	2016-06-28	"composição aerada, composição de tratamento capilar método para o tratamento capilar"
ZA201404331B (en)	2016-10-26	Substituted 1,2,5-oxadiazole compounds and their use as herbicides iii
JP2014530840A5 (es)	2015-12-10
DK2773633T3 (da)	2017-11-13	Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf.
CL2014002847A1 (es)	2015-01-30	Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
EA201000258A1 (ru)	2010-08-30	Новые гербициды
IN2015DN01331A (es)	2015-07-03
PL3070076T3 (pl)	2022-05-09	Związki amidowe lub ich sole, oraz ich zastosowanie jako rolnicze i ogrodnicze środki bakteriobójcze
JP2013536184A5 (es)	2014-06-19